Cargando…

Comparative evaluation of the Thermo fisher TaqPath™ COVID-19 combo kit with the Cepheid Xpert® Xpress SARS-CoV-2 assay for detecting SARS-CoV-2 in nasopharyngeal specimens

PURPOSE: With over 50 SARS-CoV-2 gene amplification assays that have been EUA cleared with minimal experimental validation performed, it is likely that not all of these assays are comparable in their ability to detect SARS-CoV-2 in clinical specimens. Thermo Fisher Scientific is a relatively new com...

Descripción completa

Detalles Bibliográficos
Autores principales: Granato, Paul A., Kimball, Simon R., Alkins, Brenda R., Cross, Deirdre C., Unz, Melissa M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243295/
https://www.ncbi.nlm.nih.gov/pubmed/34193072
http://dx.doi.org/10.1186/s12879-021-06347-6
_version_ 1783715730972213248
author Granato, Paul A.
Kimball, Simon R.
Alkins, Brenda R.
Cross, Deirdre C.
Unz, Melissa M.
author_facet Granato, Paul A.
Kimball, Simon R.
Alkins, Brenda R.
Cross, Deirdre C.
Unz, Melissa M.
author_sort Granato, Paul A.
collection PubMed
description PURPOSE: With over 50 SARS-CoV-2 gene amplification assays that have been EUA cleared with minimal experimental validation performed, it is likely that not all of these assays are comparable in their ability to detect SARS-CoV-2 in clinical specimens. Thermo Fisher Scientific is a relatively new company in the molecular diagnostics field and the purpose of this study was to compare the performance of the Thermo Fisher TaqPath™ Combo Kit with an established test, the Cepheid Xpert® Xpress SARS-CoV-2 assay, for its ability to detect SARS-CoV-2 in nasopharyngeal specimens. METHODS: A total of 300 randomly selected nasopharyngeal specimens were evaluated and tested by the TaqPath and GeneXpert assays. Discordant test specimens were arbitrated by performing an alternative PCR assay and Sanger sequencing. RESULTS: The TaqPath assay had a 96.7 and 99.6% positive and negative agreement respectively when compared to the Xpert Xpress test. However, after test arbitration, the three discordant specimens were arbitrated in favor of the TaqPath assay producing a positive and negative percent agreement of 100% for the TaqPath Combo Kit while the Xpress SARS-CoV-2 assay had a positive and negative percent agreement of 98.3 and 99.2% respectively. CONCLUSIONS: The TaqPath Combo Kit is a high complexity assay that compares favorably with the Xpert Xpress test and can be reliably used for the detection of SARS-CoV-2 in nasopharyngeal specimens.
format Online
Article
Text
id pubmed-8243295
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-82432952021-06-30 Comparative evaluation of the Thermo fisher TaqPath™ COVID-19 combo kit with the Cepheid Xpert® Xpress SARS-CoV-2 assay for detecting SARS-CoV-2 in nasopharyngeal specimens Granato, Paul A. Kimball, Simon R. Alkins, Brenda R. Cross, Deirdre C. Unz, Melissa M. BMC Infect Dis Research PURPOSE: With over 50 SARS-CoV-2 gene amplification assays that have been EUA cleared with minimal experimental validation performed, it is likely that not all of these assays are comparable in their ability to detect SARS-CoV-2 in clinical specimens. Thermo Fisher Scientific is a relatively new company in the molecular diagnostics field and the purpose of this study was to compare the performance of the Thermo Fisher TaqPath™ Combo Kit with an established test, the Cepheid Xpert® Xpress SARS-CoV-2 assay, for its ability to detect SARS-CoV-2 in nasopharyngeal specimens. METHODS: A total of 300 randomly selected nasopharyngeal specimens were evaluated and tested by the TaqPath and GeneXpert assays. Discordant test specimens were arbitrated by performing an alternative PCR assay and Sanger sequencing. RESULTS: The TaqPath assay had a 96.7 and 99.6% positive and negative agreement respectively when compared to the Xpert Xpress test. However, after test arbitration, the three discordant specimens were arbitrated in favor of the TaqPath assay producing a positive and negative percent agreement of 100% for the TaqPath Combo Kit while the Xpress SARS-CoV-2 assay had a positive and negative percent agreement of 98.3 and 99.2% respectively. CONCLUSIONS: The TaqPath Combo Kit is a high complexity assay that compares favorably with the Xpert Xpress test and can be reliably used for the detection of SARS-CoV-2 in nasopharyngeal specimens. BioMed Central 2021-06-30 /pmc/articles/PMC8243295/ /pubmed/34193072 http://dx.doi.org/10.1186/s12879-021-06347-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Granato, Paul A.
Kimball, Simon R.
Alkins, Brenda R.
Cross, Deirdre C.
Unz, Melissa M.
Comparative evaluation of the Thermo fisher TaqPath™ COVID-19 combo kit with the Cepheid Xpert® Xpress SARS-CoV-2 assay for detecting SARS-CoV-2 in nasopharyngeal specimens
title Comparative evaluation of the Thermo fisher TaqPath™ COVID-19 combo kit with the Cepheid Xpert® Xpress SARS-CoV-2 assay for detecting SARS-CoV-2 in nasopharyngeal specimens
title_full Comparative evaluation of the Thermo fisher TaqPath™ COVID-19 combo kit with the Cepheid Xpert® Xpress SARS-CoV-2 assay for detecting SARS-CoV-2 in nasopharyngeal specimens
title_fullStr Comparative evaluation of the Thermo fisher TaqPath™ COVID-19 combo kit with the Cepheid Xpert® Xpress SARS-CoV-2 assay for detecting SARS-CoV-2 in nasopharyngeal specimens
title_full_unstemmed Comparative evaluation of the Thermo fisher TaqPath™ COVID-19 combo kit with the Cepheid Xpert® Xpress SARS-CoV-2 assay for detecting SARS-CoV-2 in nasopharyngeal specimens
title_short Comparative evaluation of the Thermo fisher TaqPath™ COVID-19 combo kit with the Cepheid Xpert® Xpress SARS-CoV-2 assay for detecting SARS-CoV-2 in nasopharyngeal specimens
title_sort comparative evaluation of the thermo fisher taqpath™ covid-19 combo kit with the cepheid xpert® xpress sars-cov-2 assay for detecting sars-cov-2 in nasopharyngeal specimens
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243295/
https://www.ncbi.nlm.nih.gov/pubmed/34193072
http://dx.doi.org/10.1186/s12879-021-06347-6
work_keys_str_mv AT granatopaula comparativeevaluationofthethermofishertaqpathcovid19combokitwiththecepheidxpertxpresssarscov2assayfordetectingsarscov2innasopharyngealspecimens
AT kimballsimonr comparativeevaluationofthethermofishertaqpathcovid19combokitwiththecepheidxpertxpresssarscov2assayfordetectingsarscov2innasopharyngealspecimens
AT alkinsbrendar comparativeevaluationofthethermofishertaqpathcovid19combokitwiththecepheidxpertxpresssarscov2assayfordetectingsarscov2innasopharyngealspecimens
AT crossdeirdrec comparativeevaluationofthethermofishertaqpathcovid19combokitwiththecepheidxpertxpresssarscov2assayfordetectingsarscov2innasopharyngealspecimens
AT unzmelissam comparativeevaluationofthethermofishertaqpathcovid19combokitwiththecepheidxpertxpresssarscov2assayfordetectingsarscov2innasopharyngealspecimens